Search Results

Lapatinib plus letrozole for postmenopausal patients with advanced HER2⁺/HR⁺ breast cancer

Author: Guarneri, Valentina

Source: Expert Review of Anticancer Therapy, Volume 9, Number 11, November 2009 , pp. 1549-1557(9)

Publisher: Expert Reviews

Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols

Authors: Ozmen, Batuhan; Sönmezer, Murat; Atabekoglu, Cem Somer; Olmus, Hülya

Source: Reproductive BioMedicine Online, Volume 19, Number 4, October 2009 , pp. 478-485(8)

Publisher: Reproductive Healthcare Ltd

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Authors: Rabaglio, M.; Sun, Z.; Price, K. N.; Castiglione-Gertsch, M.; Hawle, H.; Thrlimann, B.; Mouridsen, H.; Campone, M.; Forbes, J. F.; Paridaens, R. J.; Colleoni, M.; Pienkowski, T.; Nogaret, J.-M.; Lng, I.; Smith, I.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S.

Source: Annals of Oncology, Volume 20, Number 9, 24 September 2009 , pp. 1489-1498(10)

Publisher: Oxford University Press

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer

Authors: Yamashita, Hiroko; Takahashi, Satoru; Ito, Yukashi; Yamashita, Toshinari; Ando, Yoshiaki; Toyama, Tatsuya; Sugiura, Hiroshi; Yoshimoto, Nobuyasu; Kobayashi, Shunzo; Fujii, Yoshitaka; Iwase, Hirotaka

Source: Cancer Science, Volume 100, Number 11, November 2009 , pp. 2028-2033(6)

Publisher: Blackwell Publishing

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

Authors: Jeong, Seongwook; Woo, Margaret; Flockhart, David; Desta, Zeruesenay

Source: Cancer Chemotherapy and Pharmacology, Volume 64, Number 5, October 2009 , pp. 867-875(9)

Publisher: Springer

Effects of oestrogen agonists on human dermal fibroblasts in an in vitro wounding assay

Authors: Stevenson, Susan; Sharpe, David T.; Julie Thornton, M.

Source: Experimental Dermatology, Volume 18, Number 11, November 2009 , pp. 988-990(3)

Publisher: Blackwell Publishing

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Authors: Hadji, P.; Ziller, M.; Kieback, D. G.; Dornoff, W.; Tessen, H. W.; Menschik, T.; Kuck, J.; Melchert, F.; Hasenburg, A.

Source: Annals of Oncology, Volume 20, Number 7, 10 July 2009 , pp. 1203-1209(7)

Publisher: Oxford University Press

Toxicological Effects of Tributyltin on Physiological Function of Carassius Aurats

Authors: Han, Zhao-Xiang; Lv, Chun-Xia; Li, Huang

Source: Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry (formerly Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry), Volume 39, Number 6, July 2009 , pp. 295-301(7)

Publisher: Taylor and Francis Ltd

Better treatment for breast cancer in older patients

Authors: Tran, Phuong; Fentiman, Ian S

Source: Expert Review of Anticancer Therapy, Volume 9, Number 8, August 2009 , pp. 1081-1090(10)

Publisher: Expert Reviews

Letrozole: A Review of its Use in the Treatment of Postmenopausal Women with Hormone-Responsive Early Breast Cancer

Author: Keating, Gillian M.

Source: Drugs, Volume 69, Number 12, 20 August 2009 , pp. 1681-1705(25)

Publisher: Adis International

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

Author: Buzdar, A. U.

Source: Annals of Oncology, Volume 20, Number 6, 13 June 2009 , pp. 993-999(7)

Publisher: Oxford University Press

Estrogens Regulate Humans and Rabbit Epididymal Contractility Through the RhoA/Rho-kinase Pathway

Authors: Fibbi, Benedetta; Filippi, Sandra; Morelli, Annamaria; Vignozzi, Linda; Silvestrini, Enrico; Chavalmane, Aravinda; De Vita, Giulia; Marini, Mirca; Gacci, Mauro; Manieri, Chiara; Vannelli, Gabriella Barbara; Maggi, Mario

Source: The Journal of Sexual Medicine, Volume 6, Number 8, August 2009 , pp. 2173-2186(14)

Publisher: Blackwell Publishing

Aromatase: The Enzyme and Its Inhibition

Authors: Banting, Lee; Ahmed, Sabbir

Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry, Volume 9, Number 6, July 2009 , pp. 627-641(15)

Publisher: Bentham Science Publishers

Comparison of the Effect of the Aromatase Inhibitor, Anastrazole, to the Antioestrogen, Tamoxifen Citrate, on Canine Prostate and Semen

Authors: Gonzalez, G; Guendulain, C; Maffrand, C; Gobello, C

Source: Reproduction in Domestic Animals, Volume 44, Supplement 2, July 2009 , pp. 316-319(4)

Publisher: Blackwell Publishing

Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma

Authors: Barker, L. C.; Brand, I. R.; Crawford, S. M.

Source: Current Medical Research and Opinion, Volume 25, Number 5, May 2009 , pp. 1105-1109(5)

Publisher: Informa Healthcare

Fulvestrant in Advanced Breast Cancer Following Tamoxifen and Aromatase Inhibition: A Single Center Experience

Authors: Wang, Jayson; Jain, Sandeep; Coombes, Charles R.; Palmieri, Carlo

Source: The Breast Journal, Volume 15, Number 3, May/June 2009 , pp. 247-253(7)

Publisher: Blackwell Publishing

Exemestane: A Review of its Use in Postmenopausal Women with Breast Cancer

Authors: Deeks, Emma D.; Scott, Lesley J.

Source: Drugs, Volume 69, Number 7, 14 May 2009 , pp. 889-918(30)

Publisher: Adis International

Prenatal Programming of Sexual Partner Preference: The Ram Model

Authors: Roselli, C. E.; Stormshak, F.

Source: Journal of Neuroendocrinology, Volume 21, Number 4, April 2009 , pp. 359-364(6)

Publisher: Blackwell Publishing

Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer

Authors: Falandry, C.; Canney, P. A.; Freyer, G.; Dirix, L. Y.

Source: Annals of Oncology, Volume 20, Number 4, 15 April 2009 , pp. 615-620(6)

Publisher: Oxford University Press

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

Authors: Li, T.; Christos, P. J.; Sparano, J. A.; Hershman, D. L.; Hoschander, S.; O'Brien, K.; Wright, J. J.; Vahdat, L. T.

Source: Annals of Oncology, Volume 20, Number 4, 15 April 2009 , pp. 642-647(6)

Publisher: Oxford University Press